WithdrawnPhase 3NCT04786574
A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Studying Autosomal recessive polycystic kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Principal Investigator
- Olga Sergeyeva, MD, CRNPOtsuka Pharmaceutical Development & Commercialization, Inc.
- Intervention
- Tolvaptan (OPC-41061)(drug)
- Eligibility
- All sexes
- Timeline
- 2022 – 2025
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04786574 on ClinicalTrials.govOther trials for Autosomal recessive polycystic kidney disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07201025Imaging Assessments of ARPKD Kidney Disease ProgressionThe Cleveland Clinic
- RECRUITINGNCT06601829Congenital Hepatic Fibrosis and Autosomal Recessive Polycystic Kidney Disease in Children at Sohag University HospitalSohag University
- RECRUITINGPHASE3NCT04782258A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)Otsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGNCT01401998ARPKD Database StudyChildren's Hospital of Philadelphia
See all trials for Autosomal recessive polycystic kidney disease →